Last $142.42 USD
Change Today 0.00 / 0.00%
Volume 0.0
AKBLF On Other Exchanges
Symbol
Exchange
Copenhagen
OTC US
Berlin
OTC US
As of 8:10 PM 08/11/14 All times are local (Market data is delayed by at least 15 minutes).

alk-abello a/s (AKBLF) Key Developments

ALK-Abelló A/S Presents at Goldman Sachs 11th Annual European Medtech And Healthcare Services Conference, Sep-05-2014

ALK-Abelló A/S Presents at Goldman Sachs 11th Annual European Medtech And Healthcare Services Conference, Sep-05-2014 . Venue: London, United Kingdom. Speakers: Per Plotnikof, Director of IR & Strategic Planning.

ALK-Abelló A/S Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 through Sep-11-2014

ALK-Abelló A/S Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 through Sep-11-2014. Venue: The Grand Hyatt Hotel, New York, New York, United States. Presentation Date & Speakers: Sep-09-2014, Jens Bager, Chief Executive Officer, President and Member of the Board of Management.

ALK-Abelló A/S Reports Unaudited Earnings Results for the Second Quarter and Six Months of 2014; Revises Earnings Guidance for Fiscal 2014

ALK-Abelló A/S reported unaudited earnings results for the second quarter and six months of 2014. Revenue grew by 17% to DKK 615 million against DKK 532 a year ago. Growth was driven by a 143% increase in revenue from SLIT-tablets, mainly due to milestone payments and reimbursements from partners. EBITDA before special items grew to DKK 109 million against a loss of DKK 7 million a year ago as a result of higher revenue and lower R&D expenses. Cash flow from operations was an inflow of DKK 179 million against an outflow of DKK 5 million a year ago. The company has reported that net profit for the second quarter ended June 30, 2014 was DKK 31 million, or DKK 3.13 per diluted share, compared to a net loss of DKK 30 million, or DKK 3.08 loss per diluted share, for the same quarter ended June 30, 2013. First half revenue hence grew 15% to DKK 1,299 million against DKK 1,142 million a year ago. EBITDA before special items was DKK 320 million against DKK 94 million a year ago. The company Net profit for the six months ended June 30, 2014 was DKK 139 million, or DKK 14.04 per diluted share, compared to DKK 12 million, or DKK 1.23 per diluted share, for the same period ended June 30, 2013. For fiscal 2014, revenue is still expected to equal approximately DKK 2.4 billion. EBITDA is now expected at approximately DKK 450 million before special items, (previously, EBITDA was expected at approximately DKK 425 before special items and future income from product supply and sales royalties in North America). The outlook now includes an estimated income from product supply and sales royalties from SLIT-tablets in North America.

ALK-Abelló A/S Presents at Goldman Sachs Biotech Symposium 2014, Sep-05-2014

ALK-Abelló A/S Presents at Goldman Sachs Biotech Symposium 2014, Sep-05-2014 . Venue: London, United Kingdom. Speakers: Per Plotnikof, Director of IR & Strategic Planning.

ALK-Abelló A/S, Q2 2014 Earnings Call, Aug 13, 2014

ALK-Abelló A/S, Q2 2014 Earnings Call, Aug 13, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKBLF:US $142.42 USD 0.00

AKBLF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergy Therapeutics PLC 24.75 GBp 0.00
DBV Technologies SA €25.57 EUR +0.57
Merck & Co Inc $60.49 USD +0.18
Sanofi €88.76 EUR +0.30
Stallergenes SA €52.00 EUR -1.05
View Industry Companies
 

Industry Analysis

AKBLF

Industry Average

Valuation AKBLF Industry Range
Price/Earnings 36.3x
Price/Sales 2.8x
Price/Book 2.9x
Price/Cash Flow 33.9x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALK-ABELLO A/S, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.